IO Biotech, Inc. (IOBT)
NASDAQ (NGS) NASDAQ (NGS) Primary OTC PINK Summary
IOBT Chart
Here's Why IO Biotech, Inc. (IOBT) Looks Ripe for Bottom Fishing
IO Biotech, Inc. (IOBT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
IO Biotech, Inc. (IOBT) Upgraded to Buy: Here's Why
IO Biotech, Inc. (IOBT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
IO Biotech: A Buying Opportunity Following Phase 3 Readout In Melanoma
IO Biotech's phase 3 melanoma trial showed a strong PFS benefit, especially in true 1st-line and PD1-negative patients, despite narrowly missing statistical significance. I believe the FDA should accept a submission based on these compelling, double-blind, randomized trial results, which show consistent benefits across subgroups. Key risks include potential FDA rejection, a dilutive cash raise, and limited US patient enrollment, but upcoming catalysts could strengthen IOBT's position.
IO Biotech, Inc. (IOBT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has IO Biotech, Inc. ever had a stock split?
IO Biotech, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mai-Britt Zocca CEO | NASDAQ (NGS) Exchange | 449778109 CUSIP |
| DK Country | 80 Employees | - Last Dividend | - Last Split | 5 Nov 2021 IPO Date |
Overview
IO Biotech, Inc. represents a pioneering force within the biotherapeutic industry, focusing closely on the development of groundbreaking immune-modulating cancer vaccines. This drive is empowered by its proprietary T-win technology platform, a revolutionary approach that seeks to harness the body's immune system to fight cancer more effectively. Founded in 2014 and rooted in Copenhagen, Denmark, IO Biotech is at the forefront of clinical-stage biopharmaceutical ventures, dedicating its resources and expertise towards innovative cancer treatment solutions.
Products and Services
At the heart of IO Biotech's product pipeline is a versatile array of therapeutic candidates, each designed with precision to target specific immunosuppressive mechanisms that cancer cells exploit to evade the immune system. The company's commitment to advancing cancer treatment options manifests through its notable product candidates:
-
IO102-IO103:
As the flagship product candidate of IO Biotech, IO102-IO103 embarks on a critical mission to disrupt the cancer-fighting landscape. This innovative therapeutic vaccine aims squarely at neutralizing the immunosuppressive mechanisms enacted by key proteins, namely Indoleamine 2,3-dehydrogenase (IDO) and programmed death-ligand (PD-L1). Currently, it is undergoing a rigorous phase 3 clinical trial targeting melanoma treatment, with additional phase 2 trials to explore its efficacy against lung, head and neck, bladder, and melanoma cancers. Through this multi-faceted clinical approach, IO102-IO103 showcases the potential to redefine cancer immunotherapy.
-
IO112:
Complementing the clinical pipeline of IO Biotech is IO112, an ambitious product candidate that epitomizes the company's innovative spirit. Formulated with a singular focus, IO112 features a unique Arginase 1-derived peptide intended to prime T cells to recognize and combat cancer cells expressing Arginase 1. This specific targeting mechanism highlights IO Biotech's strategy of employing precise, immune-based interventions to tackle cancer, making IO112 a promising avenue for future cancer treatment modalities.
